Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The Michigan Cancer Consortium (with funding from the Centers for Disease Control) has developed and issued a new series of “fact sheets” under the general heading “Managing Symptoms After Prostate Cancer.”
Filed under: Management, Treatment | Leave a Comment »
The annual meeting of AORTIC (the African Organisation for Research & Training in Cancer) was held in Dar-es-Salaam, Tanzania earlier this month.
Filed under: Uncategorized | Leave a Comment »
Frankly … not that much … but a new “brief review” in BJU International provides a good summary of the little that we really do know about the variations between specific areas of human DNA (“gene polymorphism”) and the relationship of such genetic variation to risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: gene, polymorphism, variation | Leave a Comment »
So — given the paucity of prostate cancer news on this uniquely American holiday — it seemed appropriate to look back over the past 12 months and remind ourselves what, from a prostate cancer point of view, we ought to be thankful for!
Filed under: Uncategorized | Tagged: Thanksgiving | 2 Comments »
There have been several reports in the past few days that GlaxoSmithKline (GSK) has withdrawn its supplemental New Drug Application (sNDA) for approval to market dutasteride (Avodart) in the US for the prevention of prostate cancer, based on the results from the REDUCE trial, announced earlier this year.
Filed under: Prevention | Tagged: dutasteride, Prevention, REDUCE trial | Leave a Comment »
There have been a number of interesting reports over the past couple of days that are summarized briefly below. They encompass such topics as: The validity of the Epstein criteria in predicting clinically indolent prostate cancer MRI and MRSI in patient work-up prior to treatment for stage T1c disease Contrast-enhanced, color Döppler ultrasound and prostate [...]
Filed under: Uncategorized | Tagged: ADT, age, androgen deprivation therapy, color Döppler, comorbidities, Epsetin criteria, Gleason score, magnetic resonance, mortality, MRI, MRSI, testosterone, ultrasound, unilateral | 2 Comments »
For nearly 30 years, since shortly after the introduction of the so-called “nerve-sparing” radical prostatectomy by Patrick Walsh of Johns Hopkins in 1982, there has been general lack of willing in the urology community to publicly question any aspect of the value of surgery as the gold standard for the treatment of localized prostate cancer. [...]
Filed under: Uncategorized | Tagged: Andrew Vickers, Arnon Krongrad, Bertrand Guillonneau, Guy Vallancien, Patrick Walsh, radical prostatectomy | 1 Comment »
In today’s prostate cancer news reports there are brief comments on a number of interesting (if technically dense) articles dealing with such topics as: The need for regularity of post-treatment PSA testing Surgical outcomes of men with Gleason 8-10 disease over 20 years of experience Loss of penile length after radical prostatectomy Does bladder cancer invasion meet [...]
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: frequency, Gleason 8-10, outcomes, post-surgery, PSA, stage T4 | 3 Comments »
Investigators at Tokai University Hachioji Hospital in Tokyo have been using high-intensity, focused ultrasound (HIFU) to treat men with localized prostate cancer since January 1999. A newly-published paper provides a complete report on this experience.
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, outcome | Leave a Comment »
According to a Reuters report this morning, the U.S. Food and Drug Administration has advised Dendreon that the company can expect a ruling on the approval of sipuleucel-T (Provenge), the company’s investigational immunotherapeutic agent for the treatment of hormone-refractory prostate cancer, on or before May 1, 2010.
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | 3 Comments »
D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men [...]
Filed under: Management, Treatment | Tagged: comorbidity, PSA doubling time, PSA velocity, PSADT, recurrence | Leave a Comment »
Over the years a variety of factors have suggested an association between diet and risk for prostate cancer — with a particular emphasis on the “dangers” of larger quantities of things like red meat, meat fats, and milk-based products in the diet.
Filed under: Risk | Tagged: diet, risk | 7 Comments »
The CAPRA score — which stands for “Cancer of the Prostate Risk Assessment” score — was developed at the University of San Francisco as a method to assess risk of prostate cancer progression based on risk for metastases or prostate cancer-specific mortality.
Filed under: Diagnosis, Management, Risk | Tagged: CAPRA, risk, score | 1 Comment »
A few days ago we reported on a study which concluded that the addition of high-dose-rate (HDR) brachytherapy to intensity-modulated radiation therapy (IMRT) had limited short-term clinical benefit in the treatment of localized prostate cancer compared to IMRT alone. Newly published Australian data is arguably supportive of this viewpoint.
Filed under: Management, Treatment | Tagged: 3D-CRT, brachytherapy, conformational radiation therapy, HDR, high-dose-rate, outcomes, three-dimensional | Leave a Comment »
Researchers at Dartmouth-Hitchcock Medical Center in New Hampshire have analyzed the prostate cancer videos on YouTube for information content and the presence of bias. They conclude that, “although some videos are robust sources of information, given the preponderance of modest and unbalanced information among reviewed videos, YouTube is an inadequate source of prostate cancer information [...]
Filed under: Diagnosis, Management, Tips | Tagged: education, video, YouTube | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site